Medical doctors were more requested than dentists and hospitals. The use of health services was more concentrated in developed areas. The pooled results of meta-analysis suggest representativeness of Brazilian population for the last decade.
Objectives: To evaluate the Health-Related Quality of Life of elderly patient using teriparatide (TPTD) MethOds: A prospective observational study from April 2006 to February 2014 was carried out with 77 patients in a district Spanish hospital. The Health-Related Quality of Life of Patients (HRQoL) was assessed using the European Quality of Life Questionnaire (EQ-5D) before and after the TPTD therapy.A descriptive and regression analysis was done for assessing the data. Results: Mean age of patients was 75, 3 years (standard deviation, SD = 7,1 years); 4,1% were male. HRQoL of patient treated with TPTD improved from 0.36 to 0.58 EQ-5D score. The mean VAS improved (from 5.42 to 3.47), OR (2.021 to 1.695). In 80% of the patients a reduction of pain was observed as well as a reduction of fracture. cOnclusiOns: TPTD improved the HRQoL of patients studied, this data obtained can be used for cost-utility ulterior analysis.
Giving to the burden disease evaluated by Peñaloza et al. (2014), in Colombia the major depressive disorder represented the second disease with most DALYs for both genders in all age groups. Due to this result we decided to determine the economic cost of major depressive disorder in Colombia from the third-payer and patient perspectives for year 2011. MethOds: We used the official SISPRO data to get information regarding the number of visits per patient who had a diagnosis of major depressive disorder. To calculate the monetary costs, we assumed that a treatment was provided to every patient reported on the system according to the study of Pinto et al. (2010) and from the SOAT fare manual 2011 reported by the government. We multiplied the treatment cost for each patient by the total number of registers to obtain the third-payer cost. We calculated from the patient´s perspective the lost output as a result of a reduction of productivity due to major depressive disorder, using the DALYs adjusted by life expectancy, multiplied by the 2011 current GDP divided by the working-age population. Results: The total Economic impact for 2011 was USD 454.955.680. This is the result of adding the third-payer cost of USD 449.338.332 plus the patient cost of USD 5.617.347. cOnclusiOns: With this approximation to the economic impact of the major depressive disorder the government can design cost-effective mental health policies to reduce its prevalence for Colombia's population, especially for women. The cost of major depressive disorder represents 0.14% of 2011 current GDP, this means that on average there is an expenditure of USD 9.88 for each Colombian citizen to prevent the disease. Those numbers shows the importance to generate permanent public policies to improve the Colombians´ mental health.
A601inclusion of the symptoms. The heterogeneity in defining hypoglycaemia makes it difficult to compare the safety of interventions for their drug-induced hypoglycaemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.